✦ LIBER ✦

Infliximab and semen quality in men with inflammatory bowel disease

✍ Scribed by Uma Mahadevan; Jonathan P Terdiman; Jeffrey Aron; Steve Jacobsohn; Paul Turek

Book ID: 110087232
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 127 KB
Volume: 11
Category: Article
ISSN: 1078-0998
DOI: 10.1097/01.mib.0000164023.10848.c4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The effect of infliximab infusion on sem

The effect of infliximab infusion on semen quality in men with inflammatory bowel disease

✍ P.J. Turek; L. Jalalian; U. Mahadevan 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 36 KB

Peripheral neuropathy with infliximab th

Peripheral neuropathy with infliximab therapy in inflammatory bowel disease

✍ D.C. Burger; T.H.J. Florin 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB

Abnormal Semen Quality and Low Serum Tes

Abnormal Semen Quality and Low Serum Testosterone in Men with Inflammatory Bowel Disease Treated for a Long Time with Sulfasalazine

✍ G. RAGNI; G. BIANCHI PORRO; M. RUSPA; G. BARATTINI; C. LOMBARDI; M. PETRILLO 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 280 KB

Infliximab in children with inflammatory

Infliximab in children with inflammatory bowel disease in Italy: Safety

✍ M. Paganelli; P. Lionetti; G. Lombardi; A. Ravelli; A. Barabino; G. Guariso; C. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Infliximab in children with inflammatory

Infliximab in children with inflammatory bowel disease in Italy: Efficacy

✍ M. Paganelli; A. Ravelli; P. Lionetti; C. Martellossi; G. De Angelis; A. Staiano 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Are accelerated infliximab infusions saf

Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?

✍ Shivaram Bhat; Divyesh Sharma; Pauline Doherty; Tony C.K. Tham; Grant R. Caddy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

Background: Infliximab is a monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). The manufacturerrecommended administration is over 2 hours followed by 2 hours of patient observation. The data relating to adverse outcomes in patients receiving accelerated infusions for IBD